Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Stephens & Co. Maintains Equal-Weight on LiqTech International, Lowers Price Target to $3

Stephens & Co. analyst Tommy Moll maintains LiqTech International (NASDAQ:LIQT) with a Equal-Weight and lowers the price target from $6 to $3.
byBenzinga Newsdesk
March 25, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Stephens & Co. analyst Tommy Moll maintains LiqTech International (NASDAQ:LIQT) with a Equal-Weight and lowers the price target from $6 to $3.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Immuron Said Deprioritizing SARS-CoV-2 Research to Focus on Clinical Development of More Advanced Stage Therapeutic Drug Candidates

By Charles Gross
Today, 6:43 AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.

IMRN